OSE Immunotherapeutics’ Immuno-Inflammation area consists of two clinical-stage programs with promising candidates focusing on two different pathways:
– The IL-7 pathway with OSE-127 (Lusvertikimab)
OSE-127 in clinical Phase in 2 in ulcerative colitis
– The CD28 pathway with FR104
FR104 is in clinical Phase 1/2 in kidney transplant in partnership with Veloxis Pharmaceuticals, Inc.